UTIL OF HIGHLY SENS TSH-IRMA ASSAY FOR MONITORING SUPPRESSION OF PIT/AXIS

这是一项随机前瞻性研究，旨在比较完全抑制剂量与部分抑制剂量的 1-甲状腺素在缩小异常甲状腺组织方面的功效，并评估服用抑制剂量的 1-甲状腺素的患者可能发生的骨密度变化，并确定是否可以通过使用部分抑制剂量而不是完全抑制剂量的 1-甲状腺素来最大程度地减少 1-甲状腺素对周围器官的任何已记录的不良反应。 麻省总医院研究人员之前的数据表明，“抑制”剂量的甲状腺素可能与骨质疏松症有关。高度灵敏（第三代）测定可以区分部分和完全抑制的甲状腺素剂量。 目前没有足够的数据来报告任何结论。 最终数据分析将在所有患者入组并进行前瞻性随访后进行。 研究人员计划继续收集所有入组患者的数据。

This is a randomized prospective study to compare the efficacy of fully suppressive vs partially suppressive doses of 1-thyroxine in shrinking abnormal thyroid tissue, and to evaluate changes in bone density which may occur in patients taking suppressive doses of 1-thyroxine, and to determine if any documented adverse effects of 1-thyroxine on peripheral organs can be minimized by using partially suppressive, rather than fully suppressive doses of 1-thyroxine. Previous data by MGH investigators have suggested that "suppressive" doses of thyroxine may be asociated with osteoporosis. A highly sensitive (3rd generation) assay allows discrimination between partially and fully suppressive thyroxine doses. There are insufficient data to report any conclusions at the present time. Final data analysis will occur after all patients have been enrolled and prospectively followed. The investigators plan to continue to accrue data for all enrolled patients.